How Much Does Ozempic Cost Per Month?

TL;DR: Brand-name Ozempic costs approximately $970 per month without insurance. Wegovy (the higher-dose, FDA-approved weight loss version of semaglutide) runs about $1,350 per month. Insurance coverage is inconsistent: most plans cover Ozempic for type 2 diabetes but many exclude weight loss indications, and prior authorization is nearly always required. Manufacturer savings cards can reduce costs to $25 per month for eligible commercially insured patients, but those on Medicare, Medicaid, or without insurance don't qualify. Compounded semaglutide ($150 to $300 per month) was the most popular budget option until the FDA declared the semaglutide shortage resolved in early 2025, effectively ending legal compounding for most pharmacies. Novo Nordisk has announced list price reductions of up to 50% beginning in 2027. The total cost over a typical treatment course (12 to 18 months minimum) ranges from $3,600 to over $24,000.

How much does Ozempic cost per month? The short answer: roughly $970 without insurance, and the actual amount you pay varies widely depending on your insurance plan, your diagnosis, your eligibility for savings programs, and whether you can access alternatives.

Here's the full financial picture, layer by layer.

Brand-Name Ozempic: The Retail Price

Ozempic (semaglutide, manufactured by Novo Nordisk) has a list price of approximately $969 per month without insurance. This price is consistent across major pharmacy chains including CVS, Walgreens, and Walmart, with minimal variation.

Wegovy is the same active ingredient (semaglutide) at a higher dose (up to 2.4 mg weekly, compared to Ozempic's maximum of 2 mg) and is specifically FDA-approved for weight management. Its list price is higher: approximately $1,349 per month.

For context, Mounjaro and Zepbound (tirzepatide, manufactured by Eli Lilly) represent the other major GLP-1 options. Mounjaro's list price is roughly $1,050 per month, and Zepbound runs approximately $1,060 per month. For a detailed comparison of how these drugs differ in mechanism and efficacy, see the four main GLP-1 drugs.

Annualized costs without insurance or savings programs:

• Ozempic: approximately $11,600 per year
• Wegovy: approximately $16,200 per year
• Mounjaro/Zepbound: approximately $12,600 per year

These figures matter because GLP-1 treatment isn't a short-term intervention. Clinical evidence shows that most people need to continue medication indefinitely to maintain results, and stopping leads to significant weight regain in the majority of cases.

Insurance Coverage: What's Actually Covered

Insurance coverage for GLP-1 drugs is the single biggest variable in what you'll actually pay. It's also one of the most frustrating to navigate.

The diagnosis matters. Most insurance plans cover Ozempic and Mounjaro when prescribed for type 2 diabetes, since both drugs are FDA-approved for that indication. Coverage for weight management is significantly more variable. Wegovy and Zepbound are FDA-approved for obesity/overweight with at least one weight-related condition, but many commercial plans exclude anti-obesity medications entirely.

Formulary tier. When GLP-1 drugs are covered, they typically fall on Tier 3 or Tier 4 (specialty drugs), which means higher out-of-pocket costs. Expect coinsurance of 25% to 40% after your deductible is met, which still translates to $250 to $400 per month for many patients.

Prior authorization. Nearly all insurance plans require prior authorization for GLP-1 prescriptions. Approval rates on first submission hover around 35% to 50%, meaning half of initial requests are denied. Appeals can improve those odds, but the process takes time and persistence. Getting a letter of medical necessity from your prescribing doctor significantly strengthens an appeal.

Medicare Part D. As of 2026, Medicare covers Wegovy for beneficiaries who have both cardiovascular disease and obesity. Medicare covers Ozempic for type 2 diabetes. Coverage for weight management without cardiovascular disease remains limited.

Medicaid. Coverage varies dramatically by state. Some state Medicaid programs cover GLP-1 drugs for obesity, many do not.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer savings programs that can dramatically reduce out-of-pocket costs for eligible patients.

Novo Nordisk NovoCare Savings Card:

• Ozempic: as low as $25 per month (up to $150 in savings per fill)
• Wegovy: as low as $25 per month (up to $225 in savings per fill)

Eli Lilly Savings Card:

• Mounjaro: as low as $25 per month for eligible patients
• Zepbound: similar savings program available

Eligibility restrictions: These savings cards are available only to patients with commercial insurance. They cannot be used with Medicare, Medicaid, TRICARE, or any federal healthcare program. Patients who are uninsured or underinsured may qualify for separate patient assistance programs (PAPs) that provide the medication at reduced cost or free, but eligibility criteria are strict and application processes can take weeks.

Telehealth Platforms

Telehealth platforms emerged as a major access point for GLP-1 medications, particularly during the years when semaglutide was in short supply. Many of these platforms bundled the prescription, medical consultation, ongoing monitoring, and medication into a single monthly fee.

Pricing from major platforms in 2026:

• Ivim Health: $150 per month (semaglutide, including membership)
• Mochi Health: $178 per month (any semaglutide dose)
• Eden: $196 to $276 per month
• MEDVi: $179 introductory, then $299 per month

These prices typically covered compounded semaglutide, which was the same active ingredient produced by compounding pharmacies at a fraction of the brand-name cost. The regulatory landscape around compounded semaglutide has shifted significantly.

The Compounding Question

Compounded semaglutide was the most popular budget option for GLP-1 access, priced at $100 to $300 per month compared to nearly $1,000 for brand-name Ozempic. That landscape has changed.

The FDA declared the semaglutide shortage resolved in February 2025. Under federal law, pharmacies can compound copies of FDA-approved drugs only when those drugs are officially in shortage. With the shortage resolved, the legal basis for routine compounding ended. The FDA provided grace periods (60 days for state-licensed pharmacies, 90 days for outsourcing facilities), both of which expired by May 2025.

In 2026, the FDA escalated enforcement, issuing 30 warning letters to telehealth companies marketing compounded GLP-1 drugs. The agency cited concerns about dosing errors, questionable ingredient sourcing, and adverse events linked to compounded products.

What this means practically: Compounded semaglutide is no longer widely available as a lower-cost alternative. Some compounding pharmacies may still produce semaglutide for patients with documented clinical needs that commercial products can't meet (such as allergies to specific excipients or dose customization requirements), but routine cost-based compounding is effectively over. Legal challenges from compounders remain ongoing and could affect availability, but the regulatory trajectory is clear.

The Price Reduction on the Horizon

In February 2026, Novo Nordisk announced it will reduce list prices for Ozempic and Wegovy by up to 50% starting in 2027. If implemented as announced, this would bring Ozempic's list price closer to $485 per month and Wegovy's closer to $675 per month.

This reduction targets patients with high deductibles or coinsurance who pay a percentage of the list price out of pocket. Patients who already pay fixed copays through good insurance coverage may not see a meaningful change. And even at half the list price, a year of Ozempic would still cost roughly $5,800 out of pocket.

The Long-Term Cost Equation

The number that matters most is the total treatment cost, because GLP-1 therapy is ongoing for most patients.

Minimum treatment duration: 12 to 18 months to achieve significant weight loss and stabilize.

Maintenance: Clinical data shows that discontinuing the medication leads to regain of approximately two-thirds of lost weight within a year. This means many patients face a choice between indefinite medication or building alternative strategies to maintain results.

Total cost scenarios over 2 years:

• Brand-name with good insurance ($25 to $50 copay): $600 to $1,200
• Brand-name with typical Tier 3 coinsurance (30%): $7,000 to $9,700
• Brand-name without insurance: $23,300 to $32,400
• Telehealth platform (while available): $3,600 to $7,200

These numbers are why the question of Ozempic cost per month often becomes the question that changes the entire approach. For a breakdown of lower-cost pathways, see cheaper alternatives to Ozempic.

When the Cost Changes the Calculus

For many people, the financial reality of GLP-1 therapy shifts the conversation from "which drug" to "what else works."

The cost barrier is real: even with insurance, many patients face thousands of dollars in annual out-of-pocket costs. Without insurance, the numbers are prohibitive for most households. And the indefinite nature of treatment (stop the drug, regain the weight) means the total financial commitment has no clear endpoint.

This reality has pushed many people toward approaches that target the same underlying drivers of weight gain (food noise, cravings, emotional eating patterns) through different mechanisms. Natural alternatives to Ozempic that address the behavioral and subconscious roots of overeating offer a fundamentally different cost structure: a finite investment in changing the patterns, rather than an ongoing expense to suppress the symptoms.

For some people, GLP-1 medication is the right tool and worth the cost. For others, the price tag opens the door to exploring approaches that create lasting change without ongoing pharmaceutical expense. Either path is valid. Understanding the full financial picture helps you make that choice with clarity.

This article is for educational purposes and does not constitute medical or financial advice. Drug prices change frequently and vary by pharmacy, location, and insurance plan. Verify current pricing with your pharmacy and insurance provider. Never modify or discontinue prescription medication without consulting your healthcare provider.

Ready to stop fighting your cravings and start reprogramming your mind for lasting success? The Hypna AI 21-day self-hypnosis program is designed to help you rewire subconscious patterns and build a healthier relationship with food from the inside out.